Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. The team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. 

Biotechnology

DeuteRx

DeuteRx's headquarters in Andover, MA, United States

Sheila Dewitt

Vincent Jacques

Catherine Mccarty

Robert Johnston

Michael Webb

Lex Van Der Ploeg

Tim Barberich

David Simcox

Laurie Burlingame

Kim Drapkin

Bruce Maryanoff

This department provides expert guidance and support in financial and business matters.

Advisory Services

The Research and Development Advisors at DeuteRx play a crucial role in advancing the company's innovative approach to drug development. They leverage their expertise in Deuterium-Enabled Chiral Switching (DECS) to guide research initiatives and optimize the efficacy of racemic drugs, ensuring the delivery of safe and effective treatments for patients.

Research and Development Advisors

The Leadership Team at DeuteRx is responsible for setting the company's strategic vision and guiding its mission to enhance racemic drugs through innovative approaches like Deuterium-Enabled Chiral Switching (DECS). They oversee research and early development initiatives, ensure alignment with regulatory standards, and foster collaboration within the organization to drive advancements in biopharmaceuticals that benefit patients.

DeuteRx

Org chart

Board & advisors

Teams

Advisory Services

Research and Development Advisors

Leadership Team

Offices

DeuteRx

Org chart

Board & advisors

Teams

Advisory Services

Research and Development Advisors

Leadership Team

Offices

Related companies